VasoRx is a cutting-edge RNA medicine brand that focuses on developing therapeutic solutions for chronic vascular inflammation and remodeling. They specialize in treating diseases like Pulmonary Hypertension and Atherosclerosis by restoring biological vascular function. VasoRx utilizes innovative polymeric nanoparticles to deliver RNA therapies specifically to the vasculature, expanding the possibilities for cardiovascular and oncology treatments.

The company's core mission is to prevent the progression of chronic vascular inflammation and dysfunction in diseases. They have patented a molecular pathway that controls endothelial-to-mesenchymal transition, a leading cause of vascular maladaptation, inflammation, and remodeling. By utilizing their first-in-class nanoparticle therapeutics, VasoRx aims to restore vascular function, reduce chronic inflammation, and scar formation.

Their solutions result in improved pulmonary and vascular function and increased patient quality of life. VasoRx is dedicated to mitigating chronic vascular remodeling and inflammation in Pulmonary Hypertension, ultimately aiming to improve patient outcomes and well-being